Investor deadline: y-mabs therapeutics, inc. investors with substantial losses have opportunity to lead class action lawsuit - ymab

San diego, california--(newsfile corp. - january 21, 2023) - the law firm of robbins geller rudman & dowd llp announces that purchasers of y-mabs therapeutics, inc. (nasdaq: ymab) common stock on the open market, or pursuant to registration statements filed with the u.s. securities and exchange commission ("sec"), between october 6, 2020 and october 28, 2022, inclusive (the "class period") have until march 20, 2023 to seek appointment as lead plaintiff.
YMAB Ratings Summary
YMAB Quant Ranking